3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
17
Neoplasm Metastasis
9
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
3
Melanoma
3
Brain Neoplasms
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Neuroblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Colorectal Neoplasms
2
Advanced Cancer
2
Urologic Neoplasms
1
Unilateral Breast Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Multiple Myeloma
1
Interventions
Cisplatin
38
Fluorouracil
37
Radiotherapy
33
Oxaliplatin
23
Paclitaxel
20
Irinotecan
18
Leucovorin
17
Docetaxel
17
Capecitabine
10
Neoadjuvant Therapy
9
Surgical Procedures, Operative
8
Cetuximab
8
Chemotherapy, Adjuvant
7
Radiation
6
Carboplatin
6
Immunohistochemistry
5
Erlotinib Hydrochloride
5
Biopsy
5
Magnetic Resonance Spectroscopy
4
Gene Expression Profiling
4
Folfox protocol
4
Epirubicin
4
Drug Therapy
4
pembrolizumab
3
Trastuzumab
3
Microarray Analysis
3
Gefitinib
3
Fluorodeoxyglucose F18
3
Endoscopy, Digestive System
3
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Adenocarcinoma Of Esophagus
×
abemaciclib
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled